PRESS RELEASE published on 09/12/2023 at 14:30, 2 years 2 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 09/11/2023 at 14:30, 2 years 2 months ago Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
PRESS RELEASE published on 09/07/2023 at 14:30, 2 years 2 months ago Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
PRESS RELEASE published on 08/30/2023 at 14:30, 2 years 3 months ago The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
PRESS RELEASE published on 08/28/2023 at 14:30, 2 years 3 months ago Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 08/24/2023 at 13:00, 2 years 3 months ago Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
PRESS RELEASE published on 08/17/2023 at 14:30, 2 years 3 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 08/16/2023 at 14:30, 2 years 3 months ago Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
PRESS RELEASE published on 08/14/2023 at 14:00, 2 years 3 months ago Jaguar Health Reports Second Quarter 2023 Financial Results
PRESS RELEASE published on 08/10/2023 at 14:30, 2 years 3 months ago Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
Published on 12/05/2025 at 20:25, 44 minutes ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 54 minutes ago When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 19 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 49 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 24 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:58, 2 hours 11 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 2 hours 54 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 3 hours 23 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 3 hours 51 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 51 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 11 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
